Literature DB >> 9567053

Assessing placebo response using Bayesian hierarchical survival models.

D K Stangl1, J B Greenhouse.   

Abstract

The National Institute of Mental Health (NIMH) Collaborative Study of Long-Term Maintenance Drug Therapy in Recurrent Affective Illness was a multicenter randomized controlled clinical trial designed to determine the efficacy of a pharmacotherapy for the prevention of the recurrence of unipolar affective disorders. The outcome of interest in this study was the time until the recurrence of a depressive episode. The data show much heterogeneity between centers for the placebo group. The aim of this paper is to use Bayesian hierarchical survival models to investigate the heterogeneity of placebo effects among centers in the NIMH study. This heterogeneity is explored in terms of the marginal posterior distributions of parameters of interest and predictive distributions of future observations. The Gibbs sampling algorithm is used to approximate posterior and predictive distributions. Sensitivity of results to the assumption of a constant hazard survival distribution at the first stage of the hierarchy is examined by comparing results derived from a two component exponential mixture and a two component exponential changepoint model to the results derived from an exponential model. The second component of the mixture and changepoint models is assumed to be a surviving fraction. For each of these first stage parametric models sensitivity of results to second stage prior distributions is also examined.

Entities:  

Mesh:

Year:  1998        PMID: 9567053     DOI: 10.1023/a:1009644308160

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  16 in total

1.  The powerful placebo.

Authors:  H K BEECHER
Journal:  J Am Med Assoc       Date:  1955-12-24

2.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

3.  Analysis of data from multiclinic trials.

Authors:  J L Fleiss
Journal:  Control Clin Trials       Date:  1986-12

4.  Prediction and decision making using Bayesian hierarchical models.

Authors:  D K Stangl
Journal:  Stat Med       Date:  1995-10-30       Impact factor: 2.373

Review 5.  The importance of placebo effects in pain treatment and research.

Authors:  J A Turner; R A Deyo; J D Loeser; M Von Korff; W E Fordyce
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

6.  A Bayesian analysis of institutional effects in a multicenter cancer clinical trial.

Authors:  R J Gray
Journal:  Biometrics       Date:  1994-03       Impact factor: 2.571

7.  The use of mixture models for the analysis of survival data with long-term survivors.

Authors:  V T Farewell
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

8.  Methodologic issues in maintenance therapy clinical trials.

Authors:  J B Greenhouse; D Stangl; D J Kupfer; R F Prien
Journal:  Arch Gen Psychiatry       Date:  1991-04

Review 9.  Placebo as a treatment for depression.

Authors:  W A Brown
Journal:  Neuropsychopharmacology       Date:  1994-07       Impact factor: 7.853

10.  Relapse in major depressive disorder: analysis with the life table.

Authors:  M B Keller; R W Shapiro; P W Lavori; N Wolfe
Journal:  Arch Gen Psychiatry       Date:  1982-08
View more
  3 in total

1.  Assessing the impact of managed-care on the distribution of length-of-stay using Bayesian hierarchical models.

Authors:  D Stangl; G Huerta
Journal:  Lifetime Data Anal       Date:  2000-06       Impact factor: 1.588

2.  Analysis of cure rate survival data under proportional odds model.

Authors:  Yu Gu; Debajyoti Sinha; Sudipto Banerjee
Journal:  Lifetime Data Anal       Date:  2010-06-03       Impact factor: 1.588

3.  Laplacian-P-splines for Bayesian inference in the mixture cure model.

Authors:  Oswaldo Gressani; Christel Faes; Niel Hens
Journal:  Stat Med       Date:  2022-03-14       Impact factor: 2.497

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.